title: In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
abstract: OBJECTIVE
  The aim of this study was to compare outcomes among unselected patients undergoing percutaneous coronary intervention (PCI) with either sirolimus-eluting (SES) or paclitaxel-eluting stents (PES).
  
  
  BACKGROUND
  Although the benefits of both SES and PES are well-established, studies comparing these stents directly have yielded conflicting results.
  
  
  METHODS
  We used data from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry to compare in-hospital and 1-year outcomes among unselected patients undergoing nonemergent PCI with either SES or PES implantation.
  
  
  RESULTS
  Between July 2004 and June 2006, 6,035 patients underwent PCI with either SES (n = 3,443) or PES (n = 2,592) at 47 U.S. centers. Baseline clinical and angiographic characteristics were generally similar for the 2 stent types. At 1-year, there were no differences in the primary end point of cardiac death or myocardial infarction (MI) between the SES and PES groups (9.1% vs. 10.0%, p = 0.11) or in any individual end points including cardiac death, nonfatal MI, or stent thrombosis. In unadjusted analyses, target lesion revascularization (TLR) was slightly more common with SES than with PES (4.4% vs. 3.3%, p = 0.048), but this difference was no longer apparent after adjusting for baseline characteristics as well as site-related factors (adjusted hazard ratio: 1.09, 95% confidence interval: 0.78 to 1.50).
  
  
  CONCLUSIONS
  Among unselected patients undergoing PCI, adjusted rates of both ischemic complications as well as clinically important restenosis were similar for SES and PES. The unexpected finding that TLR was influenced by site characteristics suggests that the correlation between TLR and angiographic restenosis might be weaker than previously described and warrants further study.
authors.affiliation: Harvard Clinical Research Institute, Boston, Massachusetts, USA.
authors.forename: Victor
authors.initials: V
authors.lastname: Novack
authors.forename: Donald
authors.initials: D
authors.lastname: Cutlip
authors.forename: Neal
authors.initials: N
authors.lastname: Kleiman
authors.forename: Michael
authors.initials: M
authors.lastname: Pencina
authors.forename: Laura
authors.initials: L
authors.lastname: Mauri
authors.forename: Chen-Hsing
authors.initials: CH
authors.lastname: Yen
authors.forename: Peter
authors.initials: P
authors.lastname: Berger
authors.forename: Steven
authors.initials: S
authors.lastname: Goldberg
authors.forename: Mirle
authors.initials: M
authors.lastname: Kellett
authors.forename: Ronald
authors.initials: R
authors.lastname: Waksman
authors.forename: Mun
authors.initials: M
authors.lastname: Hong
authors.forename: Albert E
authors.initials: AE
authors.lastname: Raizner
authors.forename: David J
authors.initials: DJ
authors.lastname: Cohen
mesh_terms: D054058:Acute Coronary Syndrome / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000209:etiology; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D017239:Paclitaxel / Q000008:administration & dosage*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D018570:Risk Assessment; D012720:Severity of Illness Index; D020123:Sirolimus / Q000008:administration & dosage*; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel; D020123:Sirolimus